PositiveID Corp (OTCMKTS:PSID) which is a developer company of biological diagnostics and detection solutions, informed that it filed an additional U.S. patent application for its Firefly Dx real-time PCR pathogen detection system. The new application brings its patents and pending patents for Firefly Dx to total four. As per the latest update, PositiveID’s total number of patents and pending patents stood at 18.
Firefly Dx of PositiveID is designed to offer accurate and real-time diagnostic results based on PCR chemistry in handheld equipment, thereby directing to treatment scenarios where they are needed. Such kind of treatment and facility is not possible with existing diagnostics systems. The old forms of diagnostic systems require laboratory based equipment and demands long hours or even days to derive results. The new application is about effective PCR equipment that can deliver results in not more than 20 minutes. The less duration to reach results doesn’t indicate that the quality is compromised in any form.
Firefly Dx of PositiveID is targeting entire PCR market on the international platform, which is expected to cross more than $27 billion in 2015 itself. The market valuation is reflected in Research and Markets’ report on PCR Tools and Products, “A Global Market Watch.” The applications of PositiveID include point of need monitoring of several pathogenic outbreaks like Dengue Fever and Ebola. It covers agricultural screening in both domestic regions and other developing nations. The new product will also help to detect the key biological agents that act as main factors leading to mass destruction.
William J. Caragol, the CEO of PositiveID Corp (OTCMKTS:PSID) said that the team continues to strengthen company’s intellectual property position of its product development and testing measures of the system progresses. The new technology will result in a paradigm shift to the broad-based PCR market.